3-Methylglutaconic Acid

This is one of those tests that almost no one orders unless something specific is going on, but when it matters, it matters a lot. The acid your lab is measuring shows up in only trace amounts in healthy urine, so a clearly elevated reading is a flag worth taking seriously.

3-MGA (3-methylglutaconic acid) is best understood as a clue rather than a diagnosis. It points toward a small group of rare inherited conditions involving the energy-producing compartments inside your cells (called mitochondria), and it shows up in roughly 3 percent of people who get tested because of suspected metabolic disease.

What This Acid Actually Is

3-MGA is a small organic acid linked to the breakdown of leucine, one of the amino acid building blocks from the protein you eat. Leucine breakdown shares an intermediate (HMG-CoA) with the chemistry your cells use to make cholesterol and related fat-like molecules, which is why these pathways get mentioned together. 3-MGA itself, though, is not a direct intermediate in cholesterol production. In the secondary forms tied to mitochondrial dysfunction, the leading hypothesis is that 3-MGA arises from a backup route the cell uses to handle acetyl-CoA when the main energy cycle (the TCA cycle) is bogged down.

When the enzyme that normally processes this acid is broken, or when your mitochondria are struggling for other reasons, 3-MGA leaks out into the bloodstream and gets filtered into your urine. The enzyme most directly involved (called AUH) sits inside the mitochondria and acts on leucine breakdown across many tissues. In the broader group of conditions where 3-MGA shows up, the organs most often affected (brain, heart, and skeletal muscle) reflect how badly each tissue depends on mitochondrial energy, not necessarily where AUH itself is most abundant.

Primary Inherited Metabolic Disease

The cleanest signal comes from a condition called 3-methylglutaconic aciduria type I, caused by a defect in the AUH gene. In this disorder, 3-MGA levels in urine are dramatically elevated, often many times higher than the trace amounts seen in healthy people. Levels also rise sharply after a protein-rich or leucine-rich meal in this specific condition, which can help separate it from other causes.

Type I has a wide spectrum. Some people are essentially without symptoms. Others have slowly progressive neurologic problems that can show up only in adulthood as trouble with balance, tremor, or changes in brain white matter. A clear, persistent elevation of this acid combined with two related metabolites (3-methylglutaric acid and 3-hydroxyisovaleric acid) is the biochemical fingerprint that typically prompts genetic testing of the AUH gene.

Mitochondrial Membrane Disorders

A second cluster of conditions where this acid is a defining feature involves problems with the membranes and protein machinery inside mitochondria. The most studied is Barth syndrome (caused by changes in the TAZ gene), which mainly affects boys and shows up as heart muscle disease, weak skeletal muscle, low neutrophil counts, and growth delay.

Other conditions in this group include MEGDEL syndrome (SERAC1 gene), Costeff syndrome (OPA3 gene), DCMA syndrome (DNAJC19), and disorders linked to TMEM70, CLPB, TIMM50, and more recently YME1L1. These typically come with combinations of cataracts, low neutrophil counts, seizures, hearing loss, movement problems, heart muscle disease, lactic acid buildup, and developmental delay.

Broader Mitochondrial Dysfunction

Outside the clearly defined syndromes, this acid is best thought of as a general signal that something is off with mitochondrial energy production. In a large series of people with genetically proven mitochondrial disorders, roughly 1 in 9 had elevated urinary 3-MGA, especially those with problems in the ATP synthase enzyme or with depletion of mitochondrial DNA.

Elevated levels have also been reported in other organic acid disorders, urea cycle disorders, fatty acid oxidation defects, glycogen storage diseases, and Smith-Lemli-Opitz syndrome (a cholesterol synthesis problem). Pregnancy and congenital adrenal hyperplasia can also push levels up, likely through their effect on steroid hormone synthesis.

Reconciling a Confusing Pattern

Two findings from the research seem to pull in opposite directions. First, a high reading is strongly linked to mitochondrial disease. Second, classic mitochondrial conditions like Barth syndrome can sometimes occur without any elevation in this acid (3-MGA-uria is present in roughly 88 percent of Barth patients, not all of them), and a single normal urine reading does not rule them out. The framework that resolves this: 3-MGA is neither highly sensitive nor highly specific as a stand-alone marker. Standard urine organic acid testing can miss it even in confirmed cases, and many non-mitochondrial conditions can push it up. It widens the differential diagnosis when present and is one of several clues to weigh, but it is neither a stand-alone diagnosis nor a stand-alone all-clear.

Why One Reading Is Not Enough

Levels of this acid can be intermittent, especially in some of the mitochondrial syndromes where excretion fluctuates over time. A single sample that comes back normal does not rule out the conditions it is meant to detect, and a single mildly elevated sample is not, by itself, diagnostic of anything specific.

Timing also matters in young children. In Barth syndrome and TMEM70 deficiency, urinary 3-MGA can be absent in the newborn period and only appear after about 6 months of age. A normal result in a sick infant therefore does not exclude these conditions, and repeat testing later in infancy can be informative if clinical suspicion stays high.

If you have a baseline reason to suspect a metabolic problem, plan on repeat testing within 3 to 6 months and then at least yearly. If you are tracking a known condition, your specialist may want samples even more frequently, especially during illness or after dietary changes. Trend lines almost always tell you more than any single number.

When Results Can Be Misleading

A few situations can distort a single reading and lead to the wrong conclusion:

• Recent protein-rich meals: in 3-MGA type I, a protein or leucine-rich meal in the hours before collection can drive levels up, while in mitochondrial forms it usually does not. Eating patterns immediately before collection can shape the result.
• Pregnancy: excretion increases during pregnancy, likely related to steroid hormone synthesis, and is not a sign of a metabolic disease.
• Intermittent excretion: in some of the mitochondrial syndromes, this acid is shed in pulses rather than constantly. A normal result during a quiet phase does not rule out the underlying condition.
• Age in infancy: in some classic 3-MGA syndromes (such as Barth syndrome and TMEM70 deficiency), urine can look normal in the first months of life and only become abnormal later. Early negative tests should not close the door on these conditions.
• Lab-to-lab variation: quality assurance studies of urine organic acid testing show meaningful differences between labs in how reliably they detect and quantify this acid. Sticking with a single experienced metabolic lab makes trends more interpretable.

Decision Pathway for an Unexpected Result

If your reading is clearly elevated, the next step is rarely to repeat just this one acid in isolation. The standard workup combines several actions at once.

• Full urine organic acid profile: if not already done, look at the full pattern. 3-methylglutaric and 3-hydroxyisovaleric acids alongside 3-MGA point toward AUH type I. Lactic acid points toward mitochondrial dysfunction.
• Targeted blood work: lactate, blood gases, ammonia, acylcarnitines, and amino acid panels help map the broader metabolic picture.
• Specialist referral: a metabolic geneticist or specialist in mitochondrial disease should drive the workup. They will decide whether to pursue enzyme assays (such as AUH activity), targeted gene sequencing, or a broader genetic panel.
• Family screening: because these are inherited conditions, family members may benefit from organic acid testing or targeted genetic testing once a specific variant is identified.

For a borderline or mildly elevated result without symptoms, a repeat sample several weeks later combined with a clinical review is reasonable. Going straight to expensive genetic panels on a single mildly elevated reading is rarely the right call.